1. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Issue 5 (May 2022) Authors: Ostadal, Petr; Steg, Philippe Gabriel; Poulouin, Yann; Bhatt, Deepak L; Bittner, Vera A; Chua, Terrence; Diaz, Rafael; Goodman, Shaun G; Huo, Yong; Jukema, Johan Wouter; Karpov, Yuri; Pordy, Robert; Scemama, Michel; Szarek, Michael; White, Harvey D; Schwartz, Gregory G Journal: Lancet Issue: Volume 10:Issue 5(2022) Page Start: 330 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗